Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesObesity: Which drug and when?
International Journal of Clinical Practice, 08/29/07
Lean, M., et al. - Conclusions: Advancement of pharmacotherapy is expanding the battery of available drugs; the clinician is faced with an increasingly complex therapeutic decision. Which drug to use, and when, is influenced by a range of factors, discussed here. There is a large body of high quality evidence in the literature to support the presently available drugs; however, many questions remain unanswered including duration of therapy and whether longer-term goals of improved morbidity and mortality are achievable. Clinician and patient awareness of these issues will provide a more informed therapeutic decision and ultimately improve the potential for reaching the weight management targets
Today in Obesity...keeping you current
Receive free subspecialty "5-minute updates" via email
An integrative view of obesity
American Journal of Clinical Nutrition, 11/19/09
Marine Omega-3 Fatty Acid Intake: Associations with Cardiometabolic Risk and Response to Weight Loss Intervention in The Look AHEAD Study
Diabetes Care, 11/05/09
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
The Lancet, 11/09/09
Sponsor
Article Search
Sponsor